Bristol-Myers Squibb (BMY) reported Q4 EPS of $1.82, $0.09 better than the analyst estimate of $1.73. Revenue for the quarter came in at $11.4 billion versus the consensus estimate of $11.21 billion.
GUIDANCE:
Bristol-Myers Squibb sees FY2023 EPS of $7.95-$8.25, versus the consensus of $8.00. Total revenues are expected to increase by approximately 2% at reported rates and approximately 2% excluding foreign exchange.